PMA device
Digene Hybrid Capture 2 (HC2) Hpv Dna Tests
Qiagen Gaithersburg, Inc. · Kit, Dna Detection, Human Papillomavirus (MAQ, Class III) · First FDA decision Mar 16, 2000, newest May 29, 2015Cervical cancer and HPV
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
6
PMA pathway
Device trials
0
Naming "Digene Hybrid Capture"
MAUDE reports
0
Brand "Digene Hybrid Capture", since 2015
PubMed studies
167
Mentioning "Digene Hybrid Capture"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Digene Hybrid Capture 2 (HC2) Hpv Dna Tests
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 6 decisions filed under this name.
- DIGENE HYBRID CAPTURE 2 (HC2) HPV DNA TESTSPMA supplement
P890064-S032 · Decided May 29, 2015 · 31 days after receipt · Normal 180 Day Track No User Fee
Device type: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS (MAQ) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Screening for Cervical Cancer with Human Papillomavirus (HPV) TestingNational analysisReview closedCAG-00442NUpdated Sep 22, 2026
- Screening for Cervical Cancer with Human Papillomavirus (HPV)National determinationOn the books210.2.1Updated Jun 17, 2020
Clinical trials
Device studies on ClinicalTrials.gov that name "Digene Hybrid Capture", any status and sponsor, newest update first.
No registered device study names "Digene Hybrid Capture".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Digene Hybrid Capture", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MAQ
310 reports: 306 malfunction, 3 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Digene Hybrid Capture"[tiab]. The summary above synthesizes these.
- Digene Corporation.
Obiso R, Lorincz A · Pharmacogenomics · 2004
- Comparison of the digene hybrid capture 2 and Roche cobas 4800 HPV tests for detection of CIN2+ in a referral population in Japan.
Sasagawa T, Maehama T, Osaka Y, et al. · J Med Virol · 2018Comparative Study, Evaluation Study
- Comparison of digene hybrid capture 2, GeneMatrix PapilloScreen, and a PCR sequencing assay in detecting high-risk and probable high-risk oncogenic HPV genotypes in specimens from Korean women.
Bae JM, Min KT, Shin JY, et al. · Arch Virol · 2014Comparative Study, Research Support, Non-U.S. Gov't
- Comparison of the second-generation digene hybrid capture assay with the branched-DNA assay for measurement of hepatitis B virus DNA in serum.
Ho SK, Chan TM, Cheng IK, et al. · J Clin Microbiol · 1999Comparative Study, Research Support, Non-U.S. Gov't
- Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial.
Cook DA, Mei W, Smith LW, et al. · BMC Cancer · 2015Comparative Study, Randomized Controlled Trial
- Ability of the digene hybrid capture II test to identify Chlamydia trachomatis and Neisseria gonorrhoeae in cervical specimens.
Schachter J, Hook EW, McCormack WM, et al. · J Clin Microbiol · 1999Clinical Trial, Comparative Study
- Multicenter comparison of the digene hybrid capture CMV DNA assay (version 2.0), the pp65 antigenemia assay, and cell culture for detection of cytomegalovirus viremia.
Mazzulli T, Drew LW, Yen-Lieberman B, et al. · J Clin Microbiol · 1999Comparative Study, Multicenter Study
- Comparison of the Roche Cobas(®) 4800 HPV assay to Digene Hybrid Capture 2, Roche Linear Array and Roche Amplicor for Detection of High-Risk Human Papillomavirus Genotypes in Women undergoing treatment for cervical dysplasia.
Phillips S, Garland SM, Tan JH, et al. · J Clin Virol · 2015
- Human papillomavirus detection and typing in thin prep cervical cytologic specimens comparing the Digene Hybrid Capture II Assay, the Roche Linear Array HPV Genotyping Assay, and the Kurabo GeneSquare Microarray Assay.
Ermel A, Qadadri B, Morishita A, et al. · J Virol Methods · 2010Comparative Study, Evaluation Study
- Anal human papillomavirus testing with Digene's hybrid capture 2 using two different sampling methods.
Roka F, Roka J, Trost A, et al. · Dis Colon Rectum · 2008
- Comparison of the Digene Hybrid Capture System Cytomegalovirus (CMV) DNA (version 2.0), Roche CMV UL54 analyte-specific reagent, and QIAGEN RealArt CMV LightCycler PCR reagent tests using AcroMetrix OptiQuant CMV DNA quantification panels and specimens from allogeneic-stem-cell transplant recipients.
Hanson KE, Reller LB, Kurtzberg J, et al. · J Clin Microbiol · 2007Comparative Study, Evaluation Study
- Characteristics of apparently false-negative digene hybrid capture 2 high-risk HPV DNA testing.
Jastania R, Geddie WR, Chapman W, et al. · Am J Clin Pathol · 2006
Other devices of this type
Also filed under product code MAQ.
- cobas HPVRoche Molecular Systems, Inc. · PMA 2026
- BD Onclarity HPV Assay Reagent Pack (SKU 444075) and BD COR HPV Extraction Trough (SKU 444074)Becton, Dickinson and Company · PMA 2026
- Alinity m HR HPVAbbott Molecular, Inc. · PMA 2026
- Cervista Hpv Hr and Genfind KitHologic, Inc. · PMA 2014
- Cervista Hpv 16/18Hologic, Inc. · PMA 2014
- Onclarity HPV AssayBecton, Dickinson and Company · PMA 2025
- Digene HC2 High Risk Hpv Dna Test and Digene HC2 Hpv Dna TestQiagen Gaithersburg, Inc. · PMA 2014
- Digene Hybrid CAPTURE2Qiagen Gaithersburg, Inc. · PMA 2009
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.